Drug Shortage Report for XARELTO
Report ID | 215608 |
Drug Identification Number | 02510162 |
Brand name | XARELTO |
Common or Proper name | RIVAROXABAN |
Company Name | BAYER INC |
Market Status | MARKETED |
Active Ingredient(s) | RIVAROXABAN |
Strength(s) | 51.7MG |
Dosage form(s) | GRANULES FOR SUSPENSION |
Route of administration | ORAL |
Packaging size | 100 mL |
ATC code | B01AF |
ATC description | ANTITHROMBOTIC AGENTS |
Reason for shortage | Demand increase for the drug. |
Anticipated start date | 2024-01-12 |
Actual start date | 2024-01-12 |
Estimated end date | 2024-02-09 |
Actual end date | 2024-02-05 |
Shortage status | Resolved |
Updated date | 2024-02-06 |
Company comments | |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 2920 MATHESON BLVD EAST MISSISSAUGA, ONTARIO CANADA L4W 5R6 |
Company contact information | 1-800-265-7382 |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v10 | 2024-02-06 | English | Compare |
v9 | 2024-02-05 | French | Compare |
v8 | 2024-02-05 | English | Compare |
v7 | 2024-02-02 | French | Compare |
v6 | 2024-02-02 | English | Compare |
v5 | 2024-01-24 | French | Compare |
v4 | 2024-01-24 | English | Compare |
v3 | 2024-01-13 | English | Compare |
v2 | 2024-01-11 | French | Compare |
v1 | 2024-01-11 | English | Compare |
Showing 1 to 10 of 10